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Three	oral	 platelet	 P2Y12	 inhibitors,	 clopidogrel,	 prasugrel	 and	 ticagrelor,	 are	 available	 for	




at	 Sheffield,	 UK	 (2009-2015).	 Since	 prasugrel	 use	 was	 mostly	 restricted	 to	 the	 STEMI	
subgroup,	clopidogrel	and	ticagrelor	were	compared	for	all	ACS	patients	and	all	three	agents	
were	 compared	 in	 the	 STEMI	 subgroup.	 Differences	 in	 outcomes	 were	 evaluated	 at	 12	
months	by	KM	curves	and	log-rank	test	after	adjustment	for	independent	risk	factors.	






0.70,	 CI	 0.61-0.99,	 p	 =	 0.05).	 Of	 the	 7,595	 patients	 who	 underwent	 PCI,	 78	 (1.0%)	 had	
definite	 stent	 thrombosis	 by	 12	 months.	 Patients	 treated	 with	 ticagrelor	 had	 a	 lower	
incidence	 of	 definite	 stent	 thrombosis	 compared	 with	 clopidogrel	 (0.6%	 vs.	 1.1%;	 adjHR	
0.51,	 CI	 0.29-0.89,	 p=0.03).	 In	 the	 STEMI	 subgroup,	 there	 was	 no	 significant	 difference	
between	the	three	groups	(ticagrelor	1.0%,	clopidogrel=1.5%,	prasugrel=1.6%;	p=0.29).		
In	 conclusion,	 ticagrelor	 was	 superior	 to	 clopidogrel	 for	 reduction	 of	 both	 mortality	 and	
stent	 thrombosis	 in	 unselected	 invasively-managed	 ACS	 patients.	 In	 STEMI	 patients,	 both	
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Age	(years)	 64.4	(+/-12.9)	 63.5	(+/-12.7)	 <0.001	
Male	 3166	(68%)	 3466	(70%)	 0.009	
STEMI	 1130	(24%)	 1654	(34%)	 <0.001	
Renal	impairment	 45	(1%)	 107	(2%)	 <0.001	
Diabetes	mellitus	 687	(15%)	 798	(16%)	 0.05	
Previous	stroke/TIA	 143	(3%)	 144	(3%)	 0.68	
Previous	PCI	 320	(7%)	 359	(7%)	 0.42	
Previous	CABG	 149	(3%)	 141	(3%)	 0.34	
GP	IIb/IIIa	inhibitor	 581	(12%)	 634	(13%)	 0.55	
LMS	>50%	 340	(7.3%)	 226	(4.6%)	 <0.001	
Hypertension	 1882	(40%)	 2140	(44%)	 0.002	
Dyslipidaemia	(treated)	 2144	(46%)	 1903	(39%)	 <0.001	
3-vessel	disease	 1002	(22%)	 745	(15%)	 <0.001	
PCI	 2880	(62%)	 3353	(68%)	 <0.001	
		No.	of	vessels	attempted	 1.2	+/-	0.48	 1.2	+/-	0.47	 0.801	
		No.	of	stents	used	 1.59+/-	0.92	 1.47+/-	0.87	 <0.001	

























Age	(years)	 65.2	+/-	13.7	 60.8	+/-	11.7	 62.8	+/-12.9	 <0.001	
Male	 804	(71%)	 870	(77%)	 1189	(72%)	 0.005	
Renal	impairment	 12	(1%)	 7	(1%)	 23	(1%)	 0.144	
Diabetes	mellitus	 141	(13%)	 121	(11%)	 216	(13%)	 0.147	
Hypertension	 413	(37%)	 388	(34%)	 593	(36%)	 0.477	
Dyslipidaemia	 444	(39%)	 419	(37%)	 470	(29%)	 <0.001	
Previous	stroke/TIA	 57	(5%)	 32	(2.8%)	 40	(2%)	 <0.001	
Previous	PCI	 76	(7%)	 78	(7%)	 139	(8%)	 0.172	
Previous	CABG	 19	(2%)	 16	(1%)	 24	(1%)	 0.805	
Cardiogenic	shock	 23	(2%)	 18	(2%)	 64	(4%)	 <0.001	
GP	IIb/IIIa	inhibitors	 391	(35%)	 364	(32%)	 529	(32%)	 0.299	
LMS	>50%	 61	(5.4%)	 31	(2.7%)	 53	(3.2%)	 0.001	
3-vessel	disease	 234	(21%)	 181	(16%)	 208	(13%)	 <0.001	
PCI	 1130	(100%)	 1135	(100%)	 1616	(98%)	 <0.001	
		No.	of	vessels	attempted	 1.12+/-	0.39	 1.10	+/-	0.35	 1.09	+/-	0.39	 0.139	
		No.	of	stents	used	 1.54+/-0.81	 1.50	+/-	0.82	 1.35+/-0.77	 <0.001	





Variable	 HR	 95%	CI	 p	
Cardiogenic	shock	 7.006		 5.247-9.353	 <0.001	
Renal	impairment	 3.048	 2.199	–	4.226	 <0.001	
Emergency	procedure	 2.396	 1.959	–	2.929	 <0.001	
LMS	disease	 1.693	 1.350	–	2.124	 <0.001	
3-vessel	disease	 1.358	 1.054-1.750	 0.02	
	Clopidogrel	 1.188	 1.020-1.382	 0.03	
Age	(years)	 1.057	 1.050	–	1.064	 <0.001	
STEMI	 0.805	 0.649-0.999	 0.05	









	 Clopidogrel	 Prasugrel	 Ticagrelor	 P	value	
All	PCI-treated	ACS	patients,	n	 2880	 -	 3353	  
	Definite	ST,	n	(%)	 33	(1.1%)	 - 21	(0.6%)	 0.02	
					Acute	(%	of	total)	 11	(33%)	 - 6	(29%)	 	
					Sub-acute	(%	of	total)	 15	(45%)	 - 5	(24%)	 	
					Late	(%	of	total)	 7	(21%)	 - 10	(48%)	 	
	     
All	PCI-treated	STEMI	patients,	n	 1130	 1136	 1654	  
	Definite	ST,	n	(%) 17	(1.5%)	 18	(1.6%)	 16	(1%)	 0.29	
					Acute	(%	of	total) 6	(26%)	 11	(61%)	 6	(38%)	  
					Sub-acute	(%	of	total) 7	(48%)	 5	(28%)	 4	(25%)	  










Variable	 HR	 95%	CI	 p	
STEMI	 2.232	 1.286-3.872	 0.004	
Diabetes	 2.191	 1.189-4.037	 0.01	
Clopidogrel	 2.057	 1.187-3.565	 0.01	
Age	 0.967	 0.947-0.987	 0.001	
	STEMI:	ST-elevation	myocardial	infarction	
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